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A preclinical study has shown that a single intraperitoneal adminis-
tration of acetate (500 mg/kg) led to a fourfold increase in the tran-
scription of proopiomelanocortin (POMC) mRNA in the mouse 
hypothalamus which was linked to central appetite regulation (Frost 
et al., 2014). Acetate is formed in the colon by bacterial fermenta-
tion and tissue metabolism. Up to 70% of acetate is metabolised by 
the liver, where it is used as an energy source and substrate for the 
synthesis of cholesterol and long-chain fatty acids and as a co-sub-
strate for glutamine and glutamate synthesis (Ballard, 1972; 
Knowles et al., 1974). POMC is cleaved to peptides, including β-
endorphin, an endogenous opioid (EO) agonist that binds preferen-
tially to the opioid receptor (Castro and Morrison, 1997). In vivo 
evaluation of any acetate-induced increases in EO released in the 
human brain will help us to understand the mechanism that acetate 
may play in human appetite regulation and its mediation by opioid 
signalling. In addition, acetate administration may be a useful para-
digm to study EO release in neuropsychiatric disorders.
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Abstract
Introduction: A recent study has shown that acetate administration leads to a fourfold increase in the transcription of proopiomelanocortin (POMC) 
mRNA in the hypothalamus. POMC is cleaved to peptides, including β-endorphin, an endogenous opioid (EO) agonist that binds preferentially to 
the µ-opioid receptor (MOR). We hypothesised that an acetate challenge would increase the levels of EO in the human brain. We have previously 
demonstrated that increased EO release in the human brain can be detected using positron emission tomography (PET) with the selective MOR 
radioligand [11C]carfentanil. We used this approach to evaluate the effects of an acute acetate challenge on EO levels in the brain of healthy human 
volunteers.
Methods: Seven volunteers each completed a baseline [11C]carfentanil PET scan followed by an administration of sodium acetate before a second 
[11C]carfentanil PET scan. Dynamic PET data were acquired over 90 minutes, and corrected for attenuation, scatter and subject motion. Regional [11C] 
carfentanil BPND values were then calculated using the simplified reference tissue model (with the occipital grey matter as the reference region). 
Change in regional EO concentration was evaluated as the change in [11C]carfentanil BPND following acetate administration.
Results: Following sodium acetate administration, 2.5–6.5% reductions in [11C]carfentanil regional BPND were seen, with statistical significance 
reached in the cerebellum, temporal lobe, orbitofrontal cortex, striatum and thalamus.
Conclusions: We have demonstrated that an acute acetate challenge has the potential to increase EO release in the human brain, providing a plausible 
mechanism of the central effects of acetate on appetite in humans.
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Opioid signalling plays a key role in appetite regulation and 
the development of obesity (Bessesen and Van Gaal, 2018). 
Animal studies have shown that palatable food consumption 
releases EO (Colantuoni et al., 2001; Dum et al., 1983). Consistent 
with this evidence, a human positron emission tomography (PET) 
study reported that feeding triggers cerebral opioid release, even 
in the absence of subjective pleasure effects (Tuulari et al., 2017). 
Moreover, PET studies in subjects with obesity have shown 
reduced µ-opioid receptor (MOR) availability (Joutsa et al., 2018; 
Karlsson et al., 2015, 2016), and it has been proposed that over-
eating leads to overstimulation of the MOR and concomitant 
downregulation.
Several pharmacological and non-pharmacological stimuli have 
been evaluated as methods to increase EO release. Previous PET 
studies with [11C]carfentanil and [11C]diprenorphine have shown 
that autobiographical sad mood induction, social rejection and posi-
tive emotion processing tasks lead to a change in binding in relevant 
brain regions (Hsu et al., 2015; Koepp et al., 2009; Prossin et al., 
2016). Dexamphetamine challenge has been used successfully to 
demonstrate differences in EO release in healthy volunteers and 
patients with neuropsychiatric disorders (Colasanti et al., 2012; 
Mick et al., 2016). Moreover, development of a method that could 
enable EO release by increasing POMC transcription in patients 
with neuropsychiatric disorders is desirable, as the current methods 
use dexamphetamine, which may be challenging is some popula-
tions (e.g. psychosis or addictive disorders).
Human neuroimaging studies suggest that acetate crosses the 
blood–brain barrier (Chambers et al., 2015; Volkow et al., 2013). 
However, no data exist to indicate whether acetate could induce 
detectable changes in mu-opioid tracer binding, indicative of EO 
release, in humans. In view of these data, we used a PET imaging 
approach to test the hypothesis that an acetate challenge will 
increase the levels of EO in the brain of healthy human volunteers.
Methods
The study was approved by the West London Research Ethics 
Committee and the Administration of Radioactive Substances 
Advisory Committee, UK. Written informed consent was 
obtained from all the participants. Seven healthy male volunteers 
were recruited into the study. Participants were screened using a 
medical history and physical examination, and current/previous 
medical and mental health, as well as the history of alcohol, 
tobacco and other substance use, were assessed by a trained study 
physician using the Mini Psychiatric Interview International 
(MINI-5; Sheehan et al., 1998). Subjects with current or previous 
psychiatric disorders were excluded. Participants were also 
excluded if they drank more than 14 UK units of alcohol per 
week. Other drug use (except tobacco) was not allowed for 2 
weeks prior to the study. This was confirmed on the study day by 
a negative urine drug screen testing (cocaine, amphetamine, 
THC, methadone, opioids and benzodiazepines) and alcohol 
breath test. All subjects were asked to refrain from consuming 
caffeine and smoking on the day of the scan. None of the subjects 
met the criteria for any substance-use disorder.
All volunteers completed the [11C]carfentanil baseline PET scan 
in the morning followed by an infusion of 150 mmol of sodium ace-
tate in 1 L normal saline over 60 minutes completed 30–60 minutes 
before a second [11C]carfentanil PET scan. All subjects had light 
food (sandwich) after the first scan. There was at least an hour’s rest 
period between food intake and initiation of acetate infusion. Due to 
technical reasons such as a delay in the production or quality-control 
checks, the PET tracer was injected between 20 and 70 minutes after 
acetate infusion. Five subjects underwent both PET scans on the 
same day. For two subjects, the post-acetate scan was acquired on a 
different day for logistical reasons.
Data acquisition
Dynamic [11C]carfentanil PET scans were acquired on a HiRez 
Biograph 6 PET/computed tomography (CT) scanner (Siemens 
Healthcare, Erlangen, Germany), and data were collected con-
tinuously for 90 minutes (26 frames: 8×15 seconds, 3×60 sec-
onds, 5×120 seconds, 5×300 seconds, 5×600 seconds), 
following an intravenous injection of [11C]carfentanil (Ashok 
et al., 2019). All participants underwent a T1-weighted structural 
magnetic resonance imaging (MRI) scan (Magnetom Trio Syngo 
MR B13 Siemens 3T; Siemens AG, Medical Solutions). All the 
structural images were reviewed by an experienced neuroradiolo-
gist for unexpected findings of clinical significance, and none 
were identified.
Image analysis
The preprocessing of images and PET modelling were carried out 
using MIAKAT software (Gunn et al., 2016). There was no sig-
nificant difference in the head motion between pre and post scan. 
Regional time–activity data were sampled using the CIC neuro-
anatomical atlas after frame-by-frame motion correction of the 
dynamic PET data, (Tziortzi et al., 2011). This was applied to the 
PET image by non-linear deformation parameters derived from 
the transformation of the structural MRI into standard space. 
Previous functional MRI and preclinical studies have shown that 
food cue and consumption activates the hypothalamus, frontal 
lobe, amygdala, orbitofrontal cortex, striatum, temporal lobe, 
thalamus (Devoto et al., 2018; Volkow et al., 2012, 2017), insula 
(Wright et al., 2016), cingulate cortex (Meng et al., 2018) and 
cerebellum (Zhu and Wang, 2008), and these areas have a high 
density of MOR and can be reliably quantified. Based on these 
data, 10 grey-matter-masked regions of interest were chosen a 
priori based on the work above and the evidence of sufficient 
density of MOR that can be reliably quantified by PET imaging 
in the human brain (Colasanti et al., 2012). The simplified refer-
ence tissue model (Lammertsma and Hume, 1996) with the 
occipital lobe as the reference region (Colasanti et al., 2012) was 
used to derive regional BPND values at each PET scan. EO release 
was indexed as the fractional reduction in [11C]carfentanil BPND 









Demographic, radiochemical and binding potential parameters 
were analysed using paired t-tests (two-tailed), and values are 
expressed as the mean±standard deviation. All statistical com-
parisons were assessed using IBM SPSS Statistics for Windows 
v20.0 (IBM Corp., Armonk, NY). p-Values of <0.05 were 
accepted statistically significant.
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Results
The mean age of the group was 39.1±10.5 years, and the body 
mass index was 24±3 kg/m2. There was no significant difference 
in the injected mass (Pre-acetate vs. Post acetate: 1.93±0.33 vs. 
1.84±0.26 µg; p=0.53) and injected activity (Pre-acetate vs. Post 
acetate: 210±26.9 vs. 240±43 MBq; p=0.1). Following sodium 
acetate administration, [11C]carfentanil BPND was reduced in all 
regions and was statistically significant in the cerebellum, tempo-
ral lobe, orbitofrontal cortex, striatum and thalamus (p<0.05; 
Table 1; Figure 1). Repeated-measures analysis of variance 
showed a significant effect of acetate administration on [11C]car-
fentanil BPND measures (p<0.05). Participants did not report a 
subjective difference in appetite following acetate infusion. Our 
cerebellar and orbitofrontal cortex findings survived Benjamini–
Hochberg correction (p<0.05).
Discussion
We have shown reductions in the binding of a MOR selective 
radiotracer – [11C]carfentanil – that are consistent with an 
increase in EO release in the human brain following acetate 
administration. Our data are consistent with our hypothesis that 
an acetate challenge will increase the levels of EO in the brain of 
healthy human volunteers. The change in [11C]carfentanil bind-
ing reached statistical significance in the orbitofrontal cortex, 
striatum, thalamus, cerebellum and the temporal lobe.
A previous study in mice showed that acetate derived from 
the fermentation of carbohydrate in the colon alters POMC neu-
ron activity (Frost et al., 2014). We have now shown that periph-
eral acetate administration alters opioid signalling in the human 
brain. We did not detect a significant change in EO in the hypo-
thalamus, where acetate administration was shown to alter 
POMC expression and neuronal activity in the mouse, and the 
location of POMC-expressing neurons (Frost et al., 2014). We 
measured opioid release rather than POMC expression or neu-
ronal activity, and EO release may be expected in regions ana-
tomically distant from the neuronal cell bodies in the 
hypothalamus. If acetate stimulates the production of EO pep-
tides in hypothalamic neurons, these would be transported via 
axonal projections, and EO released in the striatum and cortical 
regions involved in food salience, where stimulation of MOR 
may occur (Cameron et al., 2017).
The mechanism of acetate-induced appetite regulation is 
speculative at this stage. The available evidence suggests that 
acetate enters the astrocytes, where it is metabolised in the TCA 
cycle, resulting in an increase in malonyl-CoA. The studies have 
also demonstrated that acetate increases the glutamate–glutamine 
cycle, triggering Ca2+ uptake. It remains unclear whether the 
changes in POMC mRNA expression (Frost et al., 2014) are 
causally related to the cellular changes above. The POMC neu-
rons are heterogeneous, with varying levels of receptor expres-
sion (Toda et al., 2017). It has been suggested that 
melanocortin–opioid interactions are crucial in the regulation of 
feeding behaviour, as they are secreted in the same vesicle 
(Millington, 2007). Our study further supports the hypothesis 
that peripheral short-chain fatty acids such as acetate regulate 
central neurochemical signalling in the key regions involved in 
appetite regulation.
Our results have implications in understanding the associa-
tion between acetate and its effect on brain regions implicated 
in the rewarding effect of alcohol. In a state of alcohol intoxica-
tion, the concentration of acetate in the blood is reported to 
increase to 0.5–1 mM (Korri et al., 1985; Orrego et al., 1988). 
Alcohol infusion has been shown to decreases brain glucose 
metabolism and increase [11C] acetate utilisation (Volkow et al., 
2013). Consistent with this study, our results show elevated EO 
levels in the brain regions reported to have increased acetate 
utilisation in the intoxicated state. In addition, acute alcohol 
ingestion is shown to release EO (Mitchell et al., 2012), and 
Table 1. BPND at baseline and after acetate administration.





Cerebellum 0.82 (0.18) 0.78 (0.18) 5.1 0.003*
Insular cortex 1.53 (0.18) 1.47 (0.23) 3.9 0.110
Temporal lobe 1.03 (0.13) 0.99 (0.11) 4.3 0.020*
Frontal lobe 0.85 (0.15) 0.82 (0.13) 3.0 0.190
Cingulate cortex 1.29 (0.21) 1.26 (0.21) 2.7 0.110
Amygdala 1.62 (0.5) 1.66 (0.16) 6.9 0.860
Orbitofrontal cortex 1.21 (0.2) 1.12 (0.16) 6.5 0.007*
Striatum 1.83 (0.17) 1.73 (0.15) 5.3 0.020*
Thalamus 1.66 (0.09) 1.57 (0.12) 5.0 0.030*
Hypothalamus 1.82 (0.24) 1.75 (0.29) 3.0 0.510
*p<0.05.
SD: standard deviation.
Figure 1. Change in [11C]carfentanil binding potential in the 
orbitofrontal cortex following administration of sodium acetate 
administration.
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there is blunting of opioid release in abstinent alcohol-depend-
ent individuals (Turton et al., 2018). Together, these studies 
show that acetate-induced opioid release may be involved in the 
hedonic response to alcohol and alcohol-induced appetite 
suppression.
Our study has certain limitations. First, this is a small sample 
size pilot study, and our findings should be replicated in a larger 
number of subjects. Although we saw a reduction in the BPND 
values across all the brain regions, statistical significance was not 
seen in the insula, frontal lobe, cingulate cortex, amygdala and 
hypothalamus. Moreover, the magnitude of the change in [11C]
carfentanil BPND PET signal is modest and may not be sufficient 
for robust quantification of dose-dependent effects. Second, we 
did not measure acetate plasma levels post administration. A pre-
vious PET study reported good brain uptake of [11C]acetate 
administered through an intravenous route (Volkow et al., 2013). 
The measurement of plasma acetate would have been useful. 
However, we felt that within the confines of a pilot study this was 
not essential, as our primary aim was to detect whether a large 
acetate load produced any effects on the brain EO system at all. 
If we were to find such an effect, subsequent investigations 
would evaluate the nature of a dose–effect relationship between 
acetate dose and magnitude of EO response. We believe that 
within the limited number of subjects in our study and the limited 
dose range used, measurement of plasma acetate would mainly 
serve the purpose of identifying subjects who have not achieved 
a meaningful increase in plasma acetate concentration due to 
experimental variability. As we administered sodium acetate by 
the intravenous route, we believe that the likelihood of substan-
tial differences in plasma acetate exposure between subjects is 
low, and hence we omitted this measurement for practical and 
logistic reasons. The dose of acetate was chosen on the basis of 
safety, by evaluating the literature and by determining the highest 
reported dose of acetate administered previously. A consistent 
elevation of acetate plasma concentration to approximately 
1.4 mmol/L was reported following the administration of 
150 mmol of sodium acetate (Akanji et al., 1990).
Second, the preclinical study suggested that POMC transcrip-
tion increased 30 minutes after acetate infusion. In our study, due 
to logistical reasons, subjects completed infusion 20–70 minutes 
before the scan, and the scan was acquired over 90 minutes. The 
time course of increases in EO following an elevation of POMC 
mRNA in the human brain is a matter of conjecture, and we may 
have missed the peak endogenous release in some or all of our 
subjects. Future microdialysis studies are needed to explore the 
b-endorphin concentration changes (Maidment et al., 1989) over 
time, following acetate administration. Third, order effect is a 
confounding factor, as our study was not counterbalanced. 
Previous studies have indicated that placebo may lead to altera-
tions in the opioid system (Pecina and Zubieta, 2015; Pecina 
et al., 2015). Follow-up studies with larger sample sizes and con-
trolling for variables such as order effects, diurnal variation and 
the potential for placebo responses will be required to test con-
clusively the hypothesis that acute acetate administration leads to 
enhanced EO levels in the human brain.
Finally, previous studies have reported [11C]carfentanil BPND 
test–retest variability of 10% (Hirvonen et al., 2009). The magni-
tude of change noted in our study is lower than this threshold. 
However, our results are consistent across brain regions in all 
study subjects.
We have demonstrated that an acute acetate challenge has the 
potential to increase EO release in the human brain, providing a 
plausible mechanism of the central effects of acetate on appetite in 
humans.
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